Free shipping on antibody orders delivered to Canada

Blog

August 09th 2019 - Multiplexed immunoassays

 

Individually united, the advantage of Parallex Bioassay multiple singleplexing solution.

read more

Four years ago, two different research teams have highlighted the possibility that the composition of the gut microbiota could modulate the efficacy of the cancer immunotherapy based on immune checkpoint inhibitors PD-L1 (1) and CTLA-4 (2).

read more
July 12th 2019 - Our antibodies at work

 

Another publication using our MM-0289-APC 28B7 for p24 double staining detection of HIV+ cells.

read more
June 19th 2019 - PSMA as a theranostic target

 

 Prostate cancer is the 3rd lethal type of cancer in the United States. Its diagnostic and stage assessment is done by histological analysis of microbiopsy, imagery, and serum marker evaluation. (1)

read more

CD44 role in T cell extravasation to inflammation site and cancer metastatic potential.

read more
May 09th 2019 - Custom companion diagnostic

 

Custom companion diagnostic, a must in drug development

read more

A team led by Dr. Chomont, had recently published an article in PLOS pathogens (Pardons, M et al 2019) where they have developed a flow cytometry approach, named HIV-flow, in order to evaluate the diversity in the phenotypes of HIV-infected cells. They have based their approach on detecting p24 positive cells.

read more

Questions, background research, hypothesis, experiments, data analysis, conclusions, repeat. 

read more

A recent publication shows that for a second time a patient was “cured” by a bone-marrow transplant. The donor had two copies of a mutation in the CCR5 gene (CD195 or C-C chemokine receptor type 5), which gives people resistance to HIV infection. For 18 month now, the patient was able to stop taking antiretroviral drugs with no detectable viral loads. This is incredibly good news however this kind of treatment wouldn’t be suitable for most people with HIV.

read more